241 related articles for article (PubMed ID: 36165913)
1. Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA as a Prediagnostic Marker for Nasopharyngeal Carcinoma.
Paudel S; Warner BE; Wang R; Adams-Haduch J; Reznik AS; Dou J; Huang Y; Gao YT; Koh WP; Bäckerholm A; Yuan JM; Shair KHY
Clin Cancer Res; 2022 Dec; 28(23):5221-5230. PubMed ID: 36165913
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Controlled Trial on Evaluation of Plasma Epstein-Barr Virus Biomarker for Early Diagnosis in Patients With Nasopharyngeal Carcinoma.
Liu W; Li H; Sheng H; Liu X; Chi P; Wang X; Mao M
Adv Ther; 2020 Oct; 37(10):4280-4290. PubMed ID: 32780356
[TBL] [Abstract][Full Text] [Related]
3. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis.
Simon J; Brenner N; Reich S; Langseth H; Hansen BT; Ursin G; Ferreiro-Iglesias A; Brennan P; Kreimer AR; Johansson M; Pring M; Nygard M; Waterboer T
Cancer Epidemiol; 2022 Apr; 77():102117. PubMed ID: 35121404
[TBL] [Abstract][Full Text] [Related]
4. High Levels of Antibody that Neutralize B-cell Infection of Epstein-Barr Virus and that Bind EBV gp350 Are Associated with a Lower Risk of Nasopharyngeal Carcinoma.
Coghill AE; Bu W; Nguyen H; Hsu WL; Yu KJ; Lou PJ; Wang CP; Chen CJ; Hildesheim A; Cohen JI
Clin Cancer Res; 2016 Jul; 22(14):3451-7. PubMed ID: 26920891
[TBL] [Abstract][Full Text] [Related]
5. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan.
Coghill AE; Hsu WL; Pfeiffer RM; Juwana H; Yu KJ; Lou PJ; Wang CP; Chen JY; Chen CJ; Middeldorp JM; Hildesheim A
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1213-9. PubMed ID: 24769890
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
Guo J; Cui Z; Zheng Y; Li X; Chen Y
Pathol Oncol Res; 2020 Oct; 26(4):2185-2190. PubMed ID: 32222897
[TBL] [Abstract][Full Text] [Related]
8. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
[TBL] [Abstract][Full Text] [Related]
9. The Relationship Between Environmental Factors and the Profile of Epstein-Barr Virus Antibodies in the Lytic and Latent Infection Periods in Healthy Populations from Endemic and Non-Endemic Nasopharyngeal Carcinoma Areas in China.
He YQ; Xue WQ; Xu FH; Xu YF; Zhang JB; Yu HL; Feng QS; Chen LZ; Cao SM; Liu Q; Mu J; Zeng YX; Jia WH
EBioMedicine; 2018 Apr; 30():184-191. PubMed ID: 29606628
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
Paramita DK; Fachiroh J; Haryana SM; Middeldorp JM
J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
[TBL] [Abstract][Full Text] [Related]
11. IgA antibodies against the Epstein-Barr nuclear antigen1 as a valuable biomarker for the diagnosis of nasopharyngeal carcinoma in Tunisian patients.
Ayadi W; Karray-Hakim H; Feki L; Khabir A; Boudawara T; Ghorbel A; Daoud J; Frikha M; Hammami A
J Med Virol; 2009 Aug; 81(8):1412-21. PubMed ID: 19551836
[TBL] [Abstract][Full Text] [Related]
12. [Six anti-Epstein-Barr virus antibodies in healthy adults in a high risk area of nasopharyngeal carcinoma].
Yi B; Gu YL; Zong YS; Cheng WM; Ji MF
Ai Zheng; 2009 Aug; 28(8):822-6. PubMed ID: 19664327
[TBL] [Abstract][Full Text] [Related]
13. Plasma Epstein-Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population.
Chen WJ; Xu WN; Wang HY; Chen XX; Li XQ; Xie SH; Lin DF; Cao SM
BMC Cancer; 2021 Jun; 21(1):651. PubMed ID: 34074258
[TBL] [Abstract][Full Text] [Related]
14. Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma.
Liu L; Zuo L; Yang J; Xin S; Zhang J; Zhou J; Li G; Tang J; Lu J
Cancer Med; 2019 Jun; 8(6):3142-3151. PubMed ID: 31063269
[TBL] [Abstract][Full Text] [Related]
15. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families.
Yu KJ; Hsu WL; Pfeiffer RM; Chiang CJ; Wang CP; Lou PJ; Cheng YJ; Gravitt P; Diehl SR; Goldstein AM; Chen CJ; Hildesheim A
Clin Cancer Res; 2011 Apr; 17(7):1906-14. PubMed ID: 21447725
[TBL] [Abstract][Full Text] [Related]
16. Association between Antibody Responses to Epstein-Barr Virus Glycoproteins, Neutralization of Infectivity, and the Risk of Nasopharyngeal Carcinoma.
Zhu QY; Kong XW; Sun C; Xie SH; Hildesheim A; Cao SM; Zeng MS
mSphere; 2020 Dec; 5(6):. PubMed ID: 33268566
[TBL] [Abstract][Full Text] [Related]
17. Plasma Macrophage Migration Inhibitory Factor and CCL3 as Potential Biomarkers for Distinguishing Patients with Nasopharyngeal Carcinoma from High-Risk Individuals Who Have Positive Epstein-Barr Virus Capsid Antigen-Specific IgA.
Xue N; Lin JH; Xing S; Liu D; Li SB; Lai YZ; Wang XP; Mao MJ; Zhong Q; Zeng MS; Liu WL
Cancer Res Treat; 2019 Jan; 51(1):378-390. PubMed ID: 29807404
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus directed screening for nasopharyngeal carcinoma in individuals with positive family history: A systematic review.
Chow JCH; Lee AWM; Wong CHL; Ng WT; Liu Z; Tay JK; Loh KS; Pace-Asciak P; Cohen O; Corry J; Rodrigo JP; Tsang RKY; Lopez F; Saba NF; de Bree R; Ferlito A
Oral Oncol; 2022 Oct; 133():106031. PubMed ID: 35908365
[TBL] [Abstract][Full Text] [Related]
19. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
[TBL] [Abstract][Full Text] [Related]
20. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
